| scholarly article | Q13442814 |
| P50 | author | Ana Espinel-Ingroff | Q108430078 |
| P2860 | cites work | Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice | Q28344589 |
| In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates | Q28345261 | ||
| Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species | Q28362760 | ||
| Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts | Q28368930 | ||
| In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods | Q28372129 | ||
| In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) | Q28379217 | ||
| Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis | Q28379219 | ||
| Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards | Q30453651 | ||
| Invasive aspergillosis caused by Aspergillus ustus: case report and review | Q33594021 | ||
| Treatment of histoplasmosis with MK-991 (L-743,872) | Q33690643 | ||
| Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase | Q33754208 | ||
| Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds | Q33960284 | ||
| Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991. | Q33960454 | ||
| In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. | Q33961573 | ||
| In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs | Q33969644 | ||
| Quality control limits for broth microdilution susceptibility tests of ten antifungal agents | Q33969748 | ||
| Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media | Q33969963 | ||
| Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi | Q33971884 | ||
| Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species | Q33974286 | ||
| Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia | Q33976842 | ||
| Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model | Q33982369 | ||
| Amphotericin B: 30 years of clinical experience | Q34028160 | ||
| Itraconazole resistance in Aspergillus fumigatus | Q35136791 | ||
| In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds | Q35137879 | ||
| Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method | Q36522007 | ||
| Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose | Q36529935 | ||
| Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi | Q36542562 | ||
| Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B. | Q36542830 | ||
| Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature | Q41508714 | ||
| In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi | Q46390314 | ||
| Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. | Q51195851 | ||
| Introduction to antifungal drugs | Q73688678 | ||
| Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature | Q74578351 | ||
| Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation | Q74579207 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 403-409 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). | |
| P478 | volume | 41 |
| Q79946556 | A case of pulmonary aspergillosis with lack of response to caspofungin |
| Q42107963 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing |
| Q41938809 | Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration |
| Q50963535 | Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. |
| Q35537846 | Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis |
| Q36257157 | Caspofungin: a review of its use in the treatment of fungal infections |
| Q46934828 | Cloning and characterization of the erg1 gene of Trichoderma harzianum: effect of the erg1 silencing on ergosterol biosynthesis and resistance to terbinafine. |
| Q36422666 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia |
| Q36066784 | Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds |
| Q38609513 | Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole |
| Q42910172 | Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates |
| Q35647724 | Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species |
| Q35215384 | Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans |
| Q42286250 | Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. |
| Q34455699 | Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience |
| Q41869129 | Establishing a method of inoculum preparation for susceptibility testing of Trichophyton rubrum and Trichophyton mentagrophytes |
| Q33753320 | Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum |
| Q34057414 | First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment |
| Q58033533 | Glucan Synthase Inhibitors |
| Q38868375 | In Vitro Antifungal Susceptibility of Yeast and Mold Phases of Isolates of Dimorphic Fungal Pathogen Emergomyces africanus (Formerly Emmonsia sp.) from HIV-Infected South African Patients. |
| Q36933432 | In Vitro Interactions between Target of Rapamycin Kinase Inhibitor and Antifungal Agents against Aspergillus Species |
| Q64228918 | In Vitro and In Vivo Evaluation of Voriconazole-Containing Antifungal Combinations against Mucorales Using a Model of Mucormycosis |
| Q39913400 | In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. |
| Q42111761 | In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing |
| Q45249831 | In vitro activity of anidulafungin. Comparison with the activity of other echinocandins |
| Q35870651 | In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection |
| Q36171554 | In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp |
| Q36492208 | In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus |
| Q51037587 | In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. |
| Q37742178 | In vitro susceptibility testing in Aspergillus species: an update |
| Q37157546 | Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species |
| Q34621506 | Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait |
| Q42432176 | Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin |
| Q34956645 | New methods to assess susceptibilities of Aspergillus isolates to caspofungin |
| Q37608276 | New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance |
| Q36491819 | Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations |
| Q57019530 | Partial silencing of a hydroxy-methylglutaryl-CoA reductase-encoding gene in Trichoderma harzianum CECT 2413 results in a lower level of resistance to lovastatin and lower antifungal activity |
| Q35913719 | Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds |
| Q88764059 | The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination |
| Q36939017 | The putative alpha-1,2-mannosyltransferase AfMnt1 of the opportunistic fungal pathogen Aspergillus fumigatus is required for cell wall stability and full virulence |
| Q37557695 | Trends in antifungal susceptibility testing using CLSI reference and commercial methods |
| Q35587108 | Utility of mould susceptibility testing |
| Q39755498 | Voriconazole inhibits fungal growth without impairing antigen presentation or T-cell activation |
| Q42116260 | Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). |
Search more.